NCT04227457已完成不适用
Prospective Epidemiological Study of Metastatic Non Small Cell Lung Cancer (NSCLC) in Latin America
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 700
- 试验地点
- 27
- 主要终点
- Overall survival of advanced NSCLC in Latin America
研究概览
简要总结
To describe the overall survival of advanced NSCLC in Latin America.
详细描述
- To describe demographic and socioeconomic characteristics of patients newly diagnosed with advanced NSCLC
- To describe diagnostic methods, pathological profile and disease stage at diagnosis of advanced NSCLC
- To describe the practice patterns of therapeutic agents for treatment of advanced NSCLC
- To describe treatment responses, progression and survival times.
- To describe reasons for treatment discontinuation
- To identify associations between patient demographics, socioeconomic, pathology, treatment sequences and overall survival;
- To define the patient experience of advanced NSCLC and identify unmet needs in their diagnose and treatment.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged 18 years or older;
- •Newly diagnosed Non-Small Cell Lung Cancer (NSCLC) during the period of the study (which includes 3 months prior to site activation by LACOG, although they can have received anti-cancer treatment during that time);
- •Histologically or cytologically confirmed advanced NSCLC:
- •Stage IIIB that progressed after curative therapy (chemoradiation and/or surgery);
- •Stage IV metastatic disease (de novo or distant relapse)
- •Any NSCLC histological subtype and molecular mutation;
- •Any Eastern Cooperative Oncology Group (ECOG) Performance Status (0 to 4) at diagnosis;
- •Patients assigned by treating physician to any therapy (i.e. chemotherapy, targeted agents, immunotherapy) or palliative care;
- •Access to patient medical chart for data collection;
- •Willing and able to provide written informed consent and privacy authorization for the release of personal health information.
排除标准
- 未提供
结局指标
主要结局
Overall survival of advanced NSCLC in Latin America
时间窗: Annually, during 3 years
Time from randomization or initiation of treatment to patient death
次要结局
- Description of socioeconomic characteristics of patients newly diagnosed with advanced NSCLC(Annually, during 3 years)
- Description of the practice patterns of therapeutic agents for treatment of advanced NSCLC(Annually, during 3 years)
- Description of the treatment responses(Annually, during 3 years)
- Description of pathological profile of advanced NSCLC(Annually, during 3 years)
- Description of Treatment discontinuation(Annually, during 3 years)
研究者
研究点 (27)
Loading locations...
相似试验
终止
不适用
Genomic Profiling in Previously Untreated Metastatic Non-small Cell Lung CancerCarcinoma, Non-small Cell LungNCT02671045Cota Inc.649
Unknown
不适用
Study of the Decrease of Length of Stereotactic Body Radiation Therapy in Lung CancerStage IA - IB Non Small Cell Lung CancerNCT03921957Centre Paul Strauss38
暂停
3 期
EGF vaccine- Advanced Lung tumorson Small Cells Lung CancerRPCEC00000161Centre of Molecular Immunology (CIM)579
已完成
不适用
An Observational Study of Tarceva (Erlotinib) in Patients With Non-Small Cell Lung CancerNon-Squamous Non-Small Cell Lung CancerNCT01488331Hoffmann-La Roche217
Unknown
不适用
Factors Determining the Prognosis in NSCLC Stage IVNSCLC Stage IVNCT04306094Instituto do Cancer do Estado de São Paulo217